<DOC>
	<DOCNO>NCT01486784</DOCNO>
	<brief_summary>This phase I/II , open-label non-randomized study use investigational new drug , TL32711 , patient AML , MDS ALL . This study target subject 60 year age old ( non-M3 AML relapse refractory disease standard therapy newly diagnose ) subject 18-59 ( relapsed refractory fail 3 prior line therapy ) . This study also target subject 18 year age old MDS ALL .</brief_summary>
	<brief_title>A Phase I-II Open Label Non-Randomized Study Using TL32711 Patients With Acute Myelogenous Leukemia , Myelodysplastic Syndrome Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>This phase I/II , open-label , non-randomized study use investigational new drug , TL 32711 , patient acute myelogenous leukemia . This study target subject 60 year age old ( non-M3 AML relapse refractory disease standard therapy newly diagnose candidate standard induction therapy ) subject 18-59 ( relapsed refractory fail 3 prior line therapy ) . Subjects would receive study drug 4 week dose period via one three different treatment schedule ( weekly , twice weekly three time weekly dosing ) . They receive treatment 6 cycle , however treatment may extend discretion study doctor felt best interest subject . Up 46 subject enrol study University Pennsylvania , depend number subject need Phase I component order determine MTD . The primary objective Phase 1 component study determine safety tolerability TL32711 , MTD patient population . The primary objective Phase 2 portion study define safety tolerability , provide preliminary efficacy data .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion Subjects diagnosis nonM3 AML , Relapsed refractory ALL Intermediate Risk 2 High Risk disease MDS follow : Subjects diagnosis nonM3 AML meet one follow criterion : 1 . Ages 60 older : Relapsed refractory least one prior therapy AML 2 . Ages 60 older : Newly diagnose patient precede history myelodysplastic syndrome treat azacitidine decitabine appropriate candidate aggressive therapy include induction follow allogeneic stem cell transplantation . 3 . Ages 1859 : Relapsed refractory disease fail three prior line therapy Subjects diagnosis relapse refractory ALL : must fail three prior line therapy 18 year age old . Subjects diagnosis Intermediate Risk 2 High Risk disease ( define IPSS score ) : must fail respond/intolerant , progress hypomethylating agent , must candidate allogeneic stem cell transplantation . 2 ) . Life expectancy least 4 week 3 ) . Must recover toxic effect prior chemotherapy 4 ) . Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing . Exclusion criteria 1. . Cytotoxic chemotherapy ( include azacitadine decitabine ) within past 28 day hydroxyurea 2. . Active participation investigational treatment study AML . 3. . ECOG performance status great 2 4. . Uncontrolled intercurrent illness include , limited : uncontrolled ongoing infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 5. . QT interval correct heart rate ( QTcB ) great 480 msec ( include subject medication ) . Subjects ventricular pacemaker QT interval measurable may eligible enrollment consultation drug manufacturer study Medical Monitor , write documentation approval . 6. . Female subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>equal great age 60 year</keyword>
	<keyword>non-M3 AML</keyword>
	<keyword>relapse disease</keyword>
	<keyword>primary refractory disease</keyword>
	<keyword>appropriate willing candidate aggressive therapy</keyword>
	<keyword>AML</keyword>
</DOC>